Antibiotic susceptibility and resistance gene analysis of Streptococcus pneumoniae in clinical tebipenem-pivoxil studies in pediatric using PCR method

Kimiko Ubukuta, Naoko Chiba, Miyuki Morozumi, Keiko Hamano-Hasegawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Among Streptococcus pneumoniae isolates from pediatric patients in Phase II and III clinical studies of tebipenem pivoxil (TBPM-PI) considered to be causative pathogens, 117 isolates were from patients with acute otitis media, 13 from those with acute sinusitis, and 21 from those with pneumonia, among the 151 strains found. We analyzed for i) pbp and macrolide-resistant genes, ii) susceptibility to antibiotics including TBPM, and iii) capsular type related to pathogenicity. The gPISP (pbp2x) isolate was identified the most at 41.1%, followed by gPRSP (pbp1a + 2x + 2b) at 34.4% and gPISP (pbp1a + 2x) at 12.6%, 94.0% of all strains had some genetic mutation and a macrolide-resistant mef (A) or erm (B) gene. TBPM showed antibacterial activity at 0.001 to 0.008 μ g/mL against gPISP (pbp2x), 0.004 to 0.031 μ g/mL against gPISP (pbp1a + 2x), and 0.008 to 0.125 μ g/mL against gPRSP, making it superior to the activity of most of antibiotics. TBPM antibacterial activity was comparable to that of panipenem. Concerning the capsular type of strains isolated from AOM patients, gPISP (pbp2x) serotype 3 composed 23.1%, followed by serotypes 19F, 6B, 14, and then 23F, among which gPRSP predominated. The coverage of isolates by 7-valent pneumococcal conjugate vaccine (7PCV) was only 48.8%. In conclusion, we expected TBPM to be bacteriological by effective against pneumococcal infection caused by gPISP and gPRSP, including AOM and pneumonia in pediatric patients.

Original languageEnglish
Pages (from-to)58-66
Number of pages9
JournalJapanese Journal of Chemotherapy
Volume57
Issue numberSUPPL. 1
Publication statusPublished - 2009 Mar
Externally publishedYes

Fingerprint

Microbial Drug Resistance
Streptococcus pneumoniae
Pediatrics
Polymerase Chain Reaction
Macrolides
Genes
Pneumonia
Anti-Bacterial Agents
Pneumococcal Infections
Conjugate Vaccines
Pneumococcal Vaccines
Sinusitis
Otitis Media
Virulence
Mutation
tebipenem
Serogroup

Keywords

  • Oral carbapenem
  • pbp gene
  • PRSP
  • Serotype
  • Streptococcus pneumoniae
  • Tebipenem

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Antibiotic susceptibility and resistance gene analysis of Streptococcus pneumoniae in clinical tebipenem-pivoxil studies in pediatric using PCR method. / Ubukuta, Kimiko; Chiba, Naoko; Morozumi, Miyuki; Hamano-Hasegawa, Keiko.

In: Japanese Journal of Chemotherapy, Vol. 57, No. SUPPL. 1, 03.2009, p. 58-66.

Research output: Contribution to journalArticle

@article{b5269e86e4bb4ee0b1b8d857bd5f1239,
title = "Antibiotic susceptibility and resistance gene analysis of Streptococcus pneumoniae in clinical tebipenem-pivoxil studies in pediatric using PCR method",
abstract = "Among Streptococcus pneumoniae isolates from pediatric patients in Phase II and III clinical studies of tebipenem pivoxil (TBPM-PI) considered to be causative pathogens, 117 isolates were from patients with acute otitis media, 13 from those with acute sinusitis, and 21 from those with pneumonia, among the 151 strains found. We analyzed for i) pbp and macrolide-resistant genes, ii) susceptibility to antibiotics including TBPM, and iii) capsular type related to pathogenicity. The gPISP (pbp2x) isolate was identified the most at 41.1{\%}, followed by gPRSP (pbp1a + 2x + 2b) at 34.4{\%} and gPISP (pbp1a + 2x) at 12.6{\%}, 94.0{\%} of all strains had some genetic mutation and a macrolide-resistant mef (A) or erm (B) gene. TBPM showed antibacterial activity at 0.001 to 0.008 μ g/mL against gPISP (pbp2x), 0.004 to 0.031 μ g/mL against gPISP (pbp1a + 2x), and 0.008 to 0.125 μ g/mL against gPRSP, making it superior to the activity of most of antibiotics. TBPM antibacterial activity was comparable to that of panipenem. Concerning the capsular type of strains isolated from AOM patients, gPISP (pbp2x) serotype 3 composed 23.1{\%}, followed by serotypes 19F, 6B, 14, and then 23F, among which gPRSP predominated. The coverage of isolates by 7-valent pneumococcal conjugate vaccine (7PCV) was only 48.8{\%}. In conclusion, we expected TBPM to be bacteriological by effective against pneumococcal infection caused by gPISP and gPRSP, including AOM and pneumonia in pediatric patients.",
keywords = "Oral carbapenem, pbp gene, PRSP, Serotype, Streptococcus pneumoniae, Tebipenem",
author = "Kimiko Ubukuta and Naoko Chiba and Miyuki Morozumi and Keiko Hamano-Hasegawa",
year = "2009",
month = "3",
language = "English",
volume = "57",
pages = "58--66",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Antibiotic susceptibility and resistance gene analysis of Streptococcus pneumoniae in clinical tebipenem-pivoxil studies in pediatric using PCR method

AU - Ubukuta, Kimiko

AU - Chiba, Naoko

AU - Morozumi, Miyuki

AU - Hamano-Hasegawa, Keiko

PY - 2009/3

Y1 - 2009/3

N2 - Among Streptococcus pneumoniae isolates from pediatric patients in Phase II and III clinical studies of tebipenem pivoxil (TBPM-PI) considered to be causative pathogens, 117 isolates were from patients with acute otitis media, 13 from those with acute sinusitis, and 21 from those with pneumonia, among the 151 strains found. We analyzed for i) pbp and macrolide-resistant genes, ii) susceptibility to antibiotics including TBPM, and iii) capsular type related to pathogenicity. The gPISP (pbp2x) isolate was identified the most at 41.1%, followed by gPRSP (pbp1a + 2x + 2b) at 34.4% and gPISP (pbp1a + 2x) at 12.6%, 94.0% of all strains had some genetic mutation and a macrolide-resistant mef (A) or erm (B) gene. TBPM showed antibacterial activity at 0.001 to 0.008 μ g/mL against gPISP (pbp2x), 0.004 to 0.031 μ g/mL against gPISP (pbp1a + 2x), and 0.008 to 0.125 μ g/mL against gPRSP, making it superior to the activity of most of antibiotics. TBPM antibacterial activity was comparable to that of panipenem. Concerning the capsular type of strains isolated from AOM patients, gPISP (pbp2x) serotype 3 composed 23.1%, followed by serotypes 19F, 6B, 14, and then 23F, among which gPRSP predominated. The coverage of isolates by 7-valent pneumococcal conjugate vaccine (7PCV) was only 48.8%. In conclusion, we expected TBPM to be bacteriological by effective against pneumococcal infection caused by gPISP and gPRSP, including AOM and pneumonia in pediatric patients.

AB - Among Streptococcus pneumoniae isolates from pediatric patients in Phase II and III clinical studies of tebipenem pivoxil (TBPM-PI) considered to be causative pathogens, 117 isolates were from patients with acute otitis media, 13 from those with acute sinusitis, and 21 from those with pneumonia, among the 151 strains found. We analyzed for i) pbp and macrolide-resistant genes, ii) susceptibility to antibiotics including TBPM, and iii) capsular type related to pathogenicity. The gPISP (pbp2x) isolate was identified the most at 41.1%, followed by gPRSP (pbp1a + 2x + 2b) at 34.4% and gPISP (pbp1a + 2x) at 12.6%, 94.0% of all strains had some genetic mutation and a macrolide-resistant mef (A) or erm (B) gene. TBPM showed antibacterial activity at 0.001 to 0.008 μ g/mL against gPISP (pbp2x), 0.004 to 0.031 μ g/mL against gPISP (pbp1a + 2x), and 0.008 to 0.125 μ g/mL against gPRSP, making it superior to the activity of most of antibiotics. TBPM antibacterial activity was comparable to that of panipenem. Concerning the capsular type of strains isolated from AOM patients, gPISP (pbp2x) serotype 3 composed 23.1%, followed by serotypes 19F, 6B, 14, and then 23F, among which gPRSP predominated. The coverage of isolates by 7-valent pneumococcal conjugate vaccine (7PCV) was only 48.8%. In conclusion, we expected TBPM to be bacteriological by effective against pneumococcal infection caused by gPISP and gPRSP, including AOM and pneumonia in pediatric patients.

KW - Oral carbapenem

KW - pbp gene

KW - PRSP

KW - Serotype

KW - Streptococcus pneumoniae

KW - Tebipenem

UR - http://www.scopus.com/inward/record.url?scp=65249087341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249087341&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:65249087341

VL - 57

SP - 58

EP - 66

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -